{'fraction_non_alphanumeric': 0.01859504132231405, 'fraction_numerical': 0.010330578512396695, 'mean_word_length': 6.072992700729927, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Drug adherence after myocardial infarction: The role of patients and physicians

Cardiovascular disease is the leading cause of death worldwide. According to the World Health Organization, in 2015 around 7.4 million people died from coronary heart disease and 6.7 million following stroke, representing about 30% of the annual mortality. By addressing modifiable risk factors in primary and secondary prevention, mortality and morbidity due to coronary artery disease can be substantially reduced. Behavioural risk factors such as tobacco use, unhealthy diet, obesity and physical inactivity can be addressed by lifestyle intervention, while other cardiovascular risk factors such as hypertension, diabetes and hyperlipidaemia need expert counselling and medical treatment. Whereas recommendations for correct secondary prevention after myocardial infarction are wellestablished, insufficient drug adherence remains a widespread problem, which impedes better outcomes.